M&A Deal Summary |
|
|---|---|
| Date | 2016-07-27 |
| Target | FirstString Research |
| Sector | Life Science |
| Buyer(s) | Relief Therapeutics Holding AG |
| Deal Type | Add-on Acquisition |
SEARCH BY
| Category | Company |
|---|---|
| Founded | 2013 |
| Sector | Life Science |
Relief Therapeutics Holding AG is a clinical-stage biotechnology company with a portfolio of drug candidates derived from natural human origins. Its two most promising drug candidates are aviptadil for the treatment of sarcoidosis (already in Phase III) and low dose interleukin-6 (atexakin alfa) for the treatment of peripheral diabetic neuropathy (already in Phase II).
| DEAL STATS | # |
|---|---|
| Overall | 1 of 2 |
| Sector: Life Science M&A | 1 of 2 |
| Type: Add-on Acquisition M&A Deals | 1 of 2 |
| State: South Carolina M&A | 1 of 1 |
| Country: United States M&A | 1 of 1 |
| Year: 2016 M&A | 1 of 1 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2021-05-04 |
APR
Balerna, Switzerland APR is a pharmaceutical company, identifying, developing, and commercializing known molecules engineered with drug delivery systems in niche and rare diseases on a global basis. The pipeline includes products at different stage of development concentrated in 3 selected therapeutic areas: inherited metabolic recessive diseases, cancer supportive care and skin rare diseases. APR was founded in 1990 and is based in Balerna, Switzerland. |
Buy | Fr.75M |
